UBS Group AG (UBS)
NYSE: UBS · Real-Time Price · USD
37.93
-0.07 (-0.18%)
At close: Jul 30, 2025, 4:00 PM
37.75
-0.18 (-0.47%)
Pre-market: Jul 31, 2025, 8:22 AM EDT
Inozyme Pharma Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Inozyme Pharma.
Price Target: $0.00 (0.00%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Inozyme Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Hold → Strong Buy Upgrades n/a | Hold → Strong Buy | Upgrades | n/a | n/a | Jun 3, 2025 |
| B of A Securities | B of A Securities | Hold → Sell Downgrades n/a | Hold → Sell | Downgrades | n/a | n/a | Mar 27, 2025 |
| Exane BNP Paribas | Exane BNP Paribas | Hold → Buy Upgrades n/a | Hold → Buy | Upgrades | n/a | n/a | Jan 3, 2025 |
| Citigroup | Citigroup | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Apr 23, 2024 |
| Morgan Stanley | Morgan Stanley | Hold → Buy Upgrades n/a | Hold → Buy | Upgrades | n/a | n/a | Mar 8, 2024 |
Financial Forecast
Revenue This Year
48.96B
from 48.03B
Increased by 1.93%
Revenue Next Year
50.33B
from 48.96B
Increased by 2.79%
EPS This Year
2.08
from 1.52
Increased by 36.87%
EPS Next Year
3.05
from 2.08
Increased by 46.37%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 61.9B | 63.4B | 66.2B | |
| Avg | 49.0B | 50.3B | 52.2B | |
| Low | 43.8B | 45.7B | 47.3B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 29.0% | 29.6% | 31.5% | |
| Avg | 1.9% | 2.8% | 3.8% | |
| Low | -8.8% | -6.8% | -6.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 2.48 | 3.57 | 4.86 | |
| Avg | 2.08 | 3.05 | 4.05 | |
| Low | 1.70 | 2.61 | 3.43 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 63.0% | 71.6% | 59.6% | |
| Avg | 36.9% | 46.4% | 32.8% | |
| Low | 11.5% | 25.3% | 12.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.